Active creative and exact outbound link observed in Meta Ad Library on October 22, 2026. The final destination was followed and its public rendered layout captured. Advertiser claims are retained as source material; creative activity does not establish performance. No personal, health or payment details were entered.

A goal-led hero introduces a paid consultation, followed by trust cards, a peptide guide, the consultation process, pricing and FAQs. Compare the creative with the destination and explore the other ads sharing this route.
Selected for its design and offer structure. Ad performance isn’t available in this collection.
The headline names the real feeling behind a confusing category (there’s too much to learn) and takes that job off the reader’s plate in the next line. “Your goals. Your labs. Your protocol.” explains the process in three words each, so the reader knows what a clinician would look at. The copy adds a gentle jab at trend-driven buying, which positions Ways2Well as the careful option. The deep blue molecule art looks clinical and premium, and it matches the page’s dark design.
The ad never tells the reader the first step costs $99, and “Build Your Protocol” suggests something free and instant. It also has no proof: no clinician face, no review, nothing that shows a real person behind the promise. If you make one like this, add a line like “Start with a $99 clinician consult” and a small photo or name of a clinician, so the click sets the right expectation and the clinician feels real.
It names the overwhelm of a confusing category in the reader’s own terms.
It hands the hard part to a clinician and shows the three inputs in one glance.
It makes the next step feel active and personal.
It positions the brand against hype buying and promises care after the first visit.
The ad links to the Ways2Well peptide consultation page, a focused landing page built around one service, which is a stronger rung than a homepage. The hero, “Peptide therapy, built around you.,” picks up the “your goals” promise directly, and a trust section with licensed clinician oversight backs up “That’s what your clinician is for.” The page also introduces the paid first step the ad never mentions: a 20-minute consult for $99, with any peptides that are prescribed billed separately. That price is explained clearly on the page, but someone who clicked “Build Your Protocol” may not expect to pay before anything is built.
The Ways2Well peptides page is a dark, goal-led landing page that sells a 20-minute, $99 clinician consult rather than a product. It moves from trust cards to goal tiles, state availability, a free peptide guide, a step-by-step process, the consult offer and FAQs. 13 ads in the Fluid library send people here, mostly statics on clinician-led reassurance and goal picking.
“Peptide therapy, built around you.” with a Book My Peptide Consult button and four trust labels answers “what is this and who is it for?”
Cards for licensed clinician oversight, FDA-regulated manufacturing, third-party testing and complete support answer “can I trust what I’d be taking?”
A section on the $99 consult says what it pays for and that peptides are billed separately, answering “what am I paying for?”
Tiles from weight loss to sexual health answer “can this address my goal?”
A grid of covered states with restrictions and an FDA disclaimer answers “can I get this where I live?”
A free, clinician-written Ultimate Peptide Guide with a Request the Guide button answers “can I learn more before I commit?”
Steps (sign up, meet with a clinician, receive your complete kit, ongoing support) answer “what happens after I book?”
A consult card restates the 20-minute, $99 visit and its inclusions, answering “what exactly do I get for $99?”
Questions on how peptides work, benefits, safety, which peptides and timing answer the remaining objections.
A medical and regulatory disclaimer sets expectations about outcomes and FDA approval.
Read the full breakdown of this page
One of 13 Ways2Well ads in the Fluid Inspiration Library, captured from the Meta Ad Library on Oct 22, 2026. We record that an ad ran publicly, not how it performed.